MSB -17%: crashed to 18 month lows today after Swiss healthcare giant Novartis walked from a deal around a treatment for COVID related respiratory issues. Novartis and Mesoblast penned a collaboration agreement last year which saw Novartis make an initial $US50m upfront payment with a $US25m equity stake. The deal could have been worth $US1.25b the remestemcel-L treatment was to achieve certain commercialisation targets and sales milestones but Novartis pulled the plug today, around 12 months after the initial day. Mesoblast remains confident the treatment is effective and trials have shown a fall in mortality rates in trials on COVID ARDS patients.
scroll
Gerrish: The correction is done, we’re positioning for what comes next
Close
Thursday 15th May – ASX -2pts, XRO, NWH, TWE
Close
A discussion with Geoff Wilson – Wilson Asset Management & James Gerrish – Market Matters
Close
Thursday 15th May – Dow off -89pts, SPI Futures off -36pts
Close
Relevant suggested news and content from the site
Video
WATCH
Gerrish: The correction is done, we’re positioning for what comes next
The Market Matters lead portfolio manager talks the recent recovery, Trump, gold, and why he thinks there's plenty of opportunities.
Podcast
LISTEN
Thursday 15th May – ASX -2pts, XRO, NWH, TWE
Daily Podcast Direct from the Desk
Video
WATCH
A discussion with Geoff Wilson – Wilson Asset Management & James Gerrish – Market Matters
Recorded Monday 31st March
Podcast
LISTEN
Thursday 15th May – Dow off -89pts, SPI Futures off -36pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.
